Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMOXICILLIN

All products: not a benefit

Other products in the same Health Canada class (J01C, J01CA) — coverage varies; not interchangeable

  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit

Novamoxin Chewable · DIN 02036347 · 125mg · chewable tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.Discontinued 2021-07-29 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Special Drugs ProgramSpecial Drugs Program: Amoxicillin, ascorbic acid (Vitamin C), deferoxamine, folic acid, hydrocortisone injection, penicillin and trimethoprim/sulfamethoxazole for the treatment of thalassaemia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novamoxin Chewable · DIN 02036347 Manufacturer: Teva Canada Limited; listing date 2008-11-04 Health Canada: Cancelled post market since 2021-07-29 · brand NOVAMOXIN · ATC J01CA04 AMOXICILLIN · form Tablet (chewable) · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 125 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15559 · Verify on the e-Formulary ↗ (DIN 02036347)

Source record
DIN 02036347: Novamoxin Chewable Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 081216090; group id 25; item number 0043; lccId None; manufacturer id TEV Source form: Chew Tab; strength: 125mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.5099; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02036347 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15559
Interchangeable products
Amoxil Chewable · DIN 02041685 · not recorded
Shortage status: discontinued (2019-10-25, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02036347
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Novamoxin (amoxicillin) may be indicated in the treatment of infections due to susceptible strains of the following micro-organisms: Gram-negative organisms: H. influenzae, P. mirabilis and N. gonorrhoeae. Gram-positive organisms: Streptococci (including Streptococcus faecalis and Streptococcus pneumoniae). Amoxicillin is not active against Pseudomonas aeruginosa, indole-positive Proteus species, Serratia marcescens, Klebsiella and Enterobacter species. In emergency cases, where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgment while awaiting bacteriologic tests to determine its antimicrobial sensitivity. Novamoxin may be indicated as a prophylaxis against alpha-hemolytic (Viridan's group) Streptococci before dental, oral or upper respiratory tract surgery or instrumentation. It may be also indicated as a prophylaxis of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constr… https://pdf.hres.ca/dpd_pm/00080491.PDF PM date: February 9, 1979 Source product: NOVAMOXIN; DIN 00406716; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Novamoxin Chewable · DIN 02036347 Shortage status: discontinued (2019-10-25, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02036347

Check this DIN again

Other review policies

For Novamoxin Chewable: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026